Fabtech Technologies FY26 Revenue Surges 28.4% to ₹431.33 Cr; Order Book ₹900+ Cr
Fabtech Technologies reported FY26 consolidated income of ₹431.33 Cr, up 28.4% YoY. EBITDA grew 18.29% to ₹55.56 Cr and PAT to ₹38.36 Cr. The order book stands at ₹900+ Cr. Key wins include projects in Saudi Arabia and Africa, with specific values like USD 7.05 million for a West Africa OSD facility.
The announcement details strong financial performance, a substantial order book, and significant strategic project wins in key international markets. These factors are likely to have a material positive impact on the company's future revenue, profitability, and market position.
The company reported strong financial growth with significant increases in revenue, EBITDA, and PAT. The order book is robust, and strategic wins in high-growth markets like Saudi Arabia and Africa indicate positive future prospects. Improvements in cash flow and debt reduction further strengthen the positive sentiment.
Fabtech Technologies Limited announced its Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The company reported a significant year-on-year increase in Total Income, which grew by 28.4% to ₹431.33 Crore.
EBITDA saw a rise of 18.29% to ₹55.56 Crore, and Operational Profit After Tax (PAT) increased by 17.4% to ₹36.6 Crore. The company's cash and bank balances saw a substantial surge of 495.7% to ₹208.57 Crore, while total equity grew by 142.5% to ₹419.77 Crore. FY26 Net Profit (PAT) stood at ₹38.36 Crore.
The company's consolidated order book was ₹900+ Crore as of March 31, 2026, providing strong revenue visibility. Key strategic wins include securing projects in Saudi Arabia for vaccine and advanced pharma facilities, and winning large-scale pharma and infrastructure projects in Africa. The West Africa Oral Solid Dosage (OSD) facility project is valued at USD 7.05 million (~₹63.6 crore) with an execution timeline of 23–27 months. Additionally, a Saudi Arabia Animal Vaccine Project is valued at USD 7.8 million (~₹65.5 crore) with an 11-month execution timeline. A North Africa Next-Generation Veterinary Facility is targeted for completion by Q1 FY27 with a project value of ₹49–52 crore.
Fabtech highlighted its asset-light, integrated model and in-house manufacturing capabilities as key differentiators. The company also reported a positive swing in operating cash flow from ₹(36.15) Crore in FY25 to ₹0.48 Crore in FY26 and a reduction in current borrowings from ₹54.09 Crore to ₹42.20 Crore.
What to do with a filing like this
Fabtech Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fabtech Technologies Limited. Read the original for the full detail.